H3K4me2 ChIP-seq upon GSK inhibiton

We show in prostate cancer cells that LSD1 co-localizes with FOXA1 and active enhancer markers (H3K4me2), and that LSD1 inhibition globally disrupts FOXA1 chromatin binding. Overall design: LNCaP cells were treated with vehicle or DHT and together with or without GSK2879552 for 24 hrs Please note that each processed data was generated from both replicates and is linked to the corresponding rep1 sample records.

本研究在前列腺癌细胞中证实，赖氨酸特异性去甲基化酶1（LSD1）可与叉头框蛋白A1（FOXA1）及活性增强子标记物H3K4me2共定位；且LSD1抑制会全局性破坏FOXA1的染色质结合能力。
实验设计概述：将LNCaP细胞分别以溶剂对照、二氢睾酮（DHT）处理，同时联合或不联合GSK2879552进行干预，处理时长为24小时。
请注意，每份经处理的数据均来自两份重复样本，并与对应的rep1样本记录相关联。